Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 and ≤ 50 years of age~* Weight of 50 to 100 kg, inclusive~* In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening~* Has access to consistent and reliable means of contact and agrees to stay in contact with the study site for the duration of the study~Exclusion Criteria:~* Any acute or chronic clinically significant disease, as determined by physical examination or laboratory screening tests~* Elevated liver function tests or safety laboratory test results~* Positive screening test for the presence of anti-CHIKV IgG~* Administration of another investigational study involving any investigational product within 60 days or 5 half-lives, whichever is longer~* Has received any live attenuated or inactive vaccines within 4 weeks prior to check-in, or plans to receive any vaccine during the study~* Known or suspected immune-mediated disease or immunosuppressive condition (including lymphoproliferative disorders)~* Any neurologic disorder~* History of idiopathic urticaria~* Any bleeding disorder that is considered a contraindication to study drug infusion or blood collection~* Receipt of immunoglobulins, a monoclonal antibody or any blood products within the preceding 6 months~* Any acute illness at the time of enrollment~* A positive test result for drugs of abuse~* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus type 1 or 2 antibodies~* A history of active cancer (malignancy) in the last 3 years~* Donation of ≥ 450 mL blood or blood products within 30 days of study drug infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- mRNA-1944 (Type: EXPERIMENTAL): Escalating dose levels
- Placebo (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).